Osteoporosis International

, Volume 18, Issue 8, pp 1033–1046 | Cite as

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women

  • J. A. Kanis
  • A. Oden
  • O. Johnell
  • H. Johansson
  • C. De Laet
  • J. Brown
  • P. Burckhardt
  • C. Cooper
  • C. Christiansen
  • S. Cummings
  • J. A. Eisman
  • S. Fujiwara
  • C. Glüer
  • D. Goltzman
  • D. Hans
  • M.-A. Krieg
  • A. La Croix
  • E. McCloskey
  • D. Mellstrom
  • L. J. MeltonIII
  • H. Pols
  • J. Reeve
  • K. Sanders
  • A-M. Schott
  • A. Silman
  • D. Torgerson
  • T. van Staa
  • N. B. Watts
  • N. Yoshimura
Original Article

Abstract

Summary

BMD and clinical risk factors predict hip and other osteoporotic fractures. The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone.

Introduction and hypotheses

To develop a risk assessment tool based on clinical risk factors (CRFs) with and without BMD.

Methods

Nine population-based studies were studied in which BMD and CRFs were documented at baseline. Poisson regression models were developed for hip fracture and other osteoporotic fractures, with and without hip BMD. Fracture risk was expressed as gradient of risk (GR, risk ratio/SD change in risk score).

Results

CRFs alone predicted hip fracture with a GR of 2.1/SD at the age of 50 years and decreased with age. The use of BMD alone provided a higher GR (3.7/SD), and was improved further with the combined use of CRFs and BMD (4.2/SD). For other osteoporotic fractures, the GRs were lower than for hip fracture. The GR with CRFs alone was 1.4/SD at the age of 50 years, similar to that provided by BMD (GR = 1.4/SD) and was not markedly increased by the combination (GR = 1.4/SD). The performance characteristics of clinical risk factors with and without BMD were validated in eleven independent population-based cohorts.

Conclusions

The models developed provide the basis for the integrated use of validated clinical risk factors in men and women to aid in fracture risk prediction.

Keywords

Bone mineral density Hip fracture Meta-analysis Osteoporotic fracture Risk assessment 

References

  1. 1.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedGoogle Scholar
  2. 2.
    Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on postmenopausal osteoporosis in women. European Agency for the Evaluation of Medicinal Products, London (CPMP/EWP/552/95 rev 1)Google Scholar
  3. 3.
    Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Rockville, MDGoogle Scholar
  4. 4.
    Royal College of Physicians (1999) Clinical Guidelines for strategies to prevent and treat osteoporosis. Royal College of Physicians, LondonGoogle Scholar
  5. 5.
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 7:390–406CrossRefGoogle Scholar
  6. 6.
    National Osteoporosis Foundation (NOF) (2003) Physician’s Guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DCGoogle Scholar
  7. 7.
    European Community (1998) Report on osteoporosis in the European Community. EC, StrasbourgGoogle Scholar
  8. 8.
    Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 167(10 Suppl):S1–S34Google Scholar
  9. 9.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRefGoogle Scholar
  10. 10.
    De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318PubMedCrossRefGoogle Scholar
  11. 11.
    Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman J, McCloskey EV, Mellstrom D, Melton LJ III, Pols H, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk. Bone 35:1029–1037PubMedCrossRefGoogle Scholar
  12. 12.
    Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  13. 13.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton III LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
  14. 14.
    Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier P, Melton LJ III, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  15. 15.
    De Laet C, Kanis JA, Oden A (2005) Body mass index as a prediction of fracture risk. A meta-analysis. Osteoporos Int, in pressGoogle Scholar
  16. 16.
    Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman A, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742PubMedCrossRefGoogle Scholar
  17. 17.
    Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, McCloskey E, Mellstrom D, Pols H, Reeve J, Silman A, Tenenhouse A (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int, in pressGoogle Scholar
  18. 18.
    Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ III, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:222–228PubMedCrossRefGoogle Scholar
  19. 19.
    Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRefGoogle Scholar
  20. 20.
    Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA (1991) Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 7:403–422PubMedCrossRefGoogle Scholar
  21. 21.
    De Laet CEDH, Van Hout BA, Burger H, Hofman A, Weel AEAM, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation of the Rotterdam Study. J Bone Miner Res 13:1587–1593PubMedCrossRefGoogle Scholar
  22. 22.
    O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1017PubMedCrossRefGoogle Scholar
  23. 23.
    Felsenberg D, Silman AJ, Lunt M, Ambrecht G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Dequeker J, Eastell R, Ershova O, Felsch B, Gowin W, Havelka S, Hoszowski K, Jajic I, Janot J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Masaryk P, Matthis C, Miazgowski T, Parisi G, Pols HAP, Poor G, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, Reeve J, O’Neill TW (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study Epos. J Bone Miner Res 17:716–724CrossRefGoogle Scholar
  24. 24.
    Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T, Naves-Diaz M, Pols HAP, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O’Neill TW (2002) Incidence of limb fracture across Europe: results from the European prospective osteoporosis study, EPOS. Osteoporosis Int 13:565–571CrossRefGoogle Scholar
  25. 25.
    Kreiger N, Tenenhouse A, Joseph L et al (1999) The canadian multicentre osteoporosis study CaMos: background, rationale, methods. Can J Ageing 18:376–387Google Scholar
  26. 26.
    Melton LJ III, Crowson CS, O’Fallon WM, Wahner HW, Riggs BL (2003) Relative contributions of bone density, bone turnover and clinical risk factors to long-term fracture prediction. J Bone Miner Res 18:312–318PubMedCrossRefGoogle Scholar
  27. 27.
    Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923PubMedCrossRefGoogle Scholar
  28. 28.
    Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimisation of BMD measurements to identify high risk groups for treatment-A test analysis. J Bone Miner Res 19:906–913PubMedCrossRefGoogle Scholar
  29. 29.
    McCloskey EV, Beneton M, Charlesworth D, Kayan K, Detakats D, Dey A, OrgeeJ, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2006) Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis-results of a double blind, placebo controlled randomised study. J Bone Miner Res 22:135–141CrossRefGoogle Scholar
  30. 30.
    Jones G, Nguyen TV, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA (1994) Symptomatic fracture incidence in elderly men and women. The Dubbo Osteoporosis Epidemiology Study DOES. Osteoporosis Int 4:277–282CrossRefGoogle Scholar
  31. 31.
    Svanborg A (1977) 70 year old people in Gothenburg. A population study in an industrialised Swedish city ii. Journal Presentation of Social and Medical Conditions. Acta Medica Scand 611(suppl):5Google Scholar
  32. 32.
    Johansson C, Black D, Johnell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190–196PubMedCrossRefGoogle Scholar
  33. 33.
    Fujiwara S, Kagasi F, Masunari N, Naito K, Suzuki G, Fukunage M (2003) Fracture prediction from bone mineral density in Japanese Men and Women. J Bone Min Res 18:1547–1553CrossRefGoogle Scholar
  34. 34.
    Fujiwara S, Kasagi F, Yamada M, Kodama K (1997) Risk factors for hip fracture in Japanese cohort. J Bone Min Res 12:998–1004CrossRefGoogle Scholar
  35. 35.
    Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas P, Ribot C, Sebert JL, Breart G, Meunier PJ (1998) How hip and whole-body bone mineral density predict hi fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 8:247–254PubMedCrossRefGoogle Scholar
  36. 36.
    Bagger YZ, Riis BJ, Alexandersen P, Tanko LB, Christiansen C (2001) Risk factors for development of osteoporosis and cardiovascular disease in postmenopausal Danish women: the PERF study. J Bone Miner Res 16:396Google Scholar
  37. 37.
    Walley T, Mantgani A (1997) The UK general practice research database. Lancet 350:1097–1099PubMedCrossRefGoogle Scholar
  38. 38.
    Gluer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Bleak T, Almbrecht G, Stewart A, Clowes J, Thomasins FE, Kolta S (2004) Association of five quantitative ultrasound devices and bone densitometry with osteoporotic fractures in a population-based source : the OPUS study. J Bone Miner Res 19:782–793PubMedCrossRefGoogle Scholar
  39. 39.
    Birks YF, Porthouse J, Addie C, Loughey K, Saxon L, Baverstock M, Francis RM, Reid DM, Watt I, Torgerson DJ (2004) Randomised controlled trial of hip protectors among women living in the Community. Osteoporosis Int 15:701–706CrossRefGoogle Scholar
  40. 40.
    Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773PubMedCrossRefGoogle Scholar
  41. 41.
    Sanders KM, Pasco JA, Ugoni A, Nicholson GC, Seeman E, Martin TJ, Skovic B, Panahi S, Kotowicz MA (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. The Geelong Osteoporosis Study. J Bone Miner Res 13:1337–1342PubMedCrossRefGoogle Scholar
  42. 42.
    Yoshimura N, Takijiri T, Kinoshita H, Danjoh S, Kasamatsu I, Morioka S, Sakato K, Hashimoto T, Takeshita T (2004) Characteristics and cause of bone mineral densities among fast bone losers in a rural Japanese community: the Miyama study. Osteoporos Int 15:139–144PubMedCrossRefGoogle Scholar
  43. 43.
    Krieg MA, Cornuz J, Ruffieux C, Burckhardt P (2004) Role des ultrasous osseux pour la prediction de fracture de la hauche chez la femme agees 70 ans ou plus: resultants de l’etude SEMOF et comparaison avec les donnees de la literature. Rev Med Suisse Rom 124:59–62PubMedGoogle Scholar
  44. 44.
    Hayes J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allan C, Rossouw JE (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77CrossRefGoogle Scholar
  45. 45.
    Anderson GL, Manson J, Wallace R, Lund B, Hall D, Dairi S, Shumcker S, Wong C-Y, Stein E, Prentice RL (2003) Implementation of the women’s health initiative study design. Ann Epidemiol 13:S5–S17PubMedCrossRefGoogle Scholar
  46. 46.
    Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2002) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis Int 12:417–424CrossRefGoogle Scholar
  47. 47.
    Edgeworth FY (1905) The law of error. Proc Cambr Philosoph Soc 20:36Google Scholar
  48. 48.
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  49. 49.
    Van der Klift M, De Laet C, McCloskey EV et al (2004) Risk factors for incident vertebral deformity in men and women: the Rotterdam study. J Bone Miner Res 19:1172–1180PubMedCrossRefGoogle Scholar
  50. 50.
    Lunt M, Felsenberg D, Reeve J et al (1997) Bone density variation and its effects on risk of vertebral deformity in men and women studied in 13 European centres: the EVOS study. J Bone Miner Res 12:1883–1894PubMedCrossRefGoogle Scholar
  51. 51.
    Silman A, O’Neill T, Cooper C et al (1997) Influence of physical activity on vertebral deformity in men and women: results from the European Vertebral Osteoporosis Study. J Bone Miner Res 12:813–819PubMedCrossRefGoogle Scholar
  52. 52.
    Nevitt MC, Cummings SR, Stone KL et al (1997) Risk factors for a first incident radiographic vertebral fracture in women ≥ years of age: The Study of Osteoporotic fracturesGoogle Scholar
  53. 53.
    Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254–1259Google Scholar
  54. 54.
    Kanis JA, Johnell O (2004) Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 16:229–238CrossRefGoogle Scholar
  55. 55.
    Kanis J, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258PubMedCrossRefGoogle Scholar
  56. 56.
    Burger H, de Laet CE, Weel AE, Hofman A, Pols HA (1999) Added value of bone mineral density in hip fracture risk scores. Bone 25:369–374PubMedCrossRefGoogle Scholar
  57. 57.
    Black DM, Steinbuch M, Palermo L, Dargent MP, Lindsay R, Hoseyni MS et al (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12:519–528PubMedCrossRefGoogle Scholar
  58. 58.
    Albrand G, Munoz F, Sornay RE, Duboeuf F, Delmas PD (2001) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY Study. Bone 32:78–85CrossRefGoogle Scholar
  59. 59.
    Carroll J, Testa M, Erat K, LeBoff M, Fuleihan G-EH (1997) Modelling fracture risk using bone density, age, and years since menopause. Am J Prev Med 13:447–452PubMedGoogle Scholar
  60. 60.
    Dargent-Molina P, Douchin MN, Cormier C, Meunier PJ, Bréart G (2002) Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study. Osteoporos Int 13:593–599PubMedCrossRefGoogle Scholar
  61. 61.
    Girman CJ, Chandler JM, Zimmerman S, I, Allison R, Hawkes W, Hebel JR et al (2002) Prediction of fracture in nursing home residents. J Am Geriatr Soc 50:1341–1347PubMedCrossRefGoogle Scholar
  62. 62.
    Honkanen RJ, Honkanen K, Kroger H, Alhava E, Tuppurainen M, Saarikoski S (2000) Risk factors for perimenopausal distal forearm fractures. Osteoporos Int 11:265–270PubMedCrossRefGoogle Scholar
  63. 63.
    Leslie WD, Metge C, Salamon EA, Yuen CK (2002) Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. J Clin Densitom 5:117–130PubMedCrossRefGoogle Scholar
  64. 64.
    Miller PD, Barles S, Brenneman SK, Abbott TA, Ya T, Barrett CE et al (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Int Med 164:1113–1120CrossRefGoogle Scholar
  65. 65.
    Westfall G, Littlefield R, Heaton A, Martin S (2001) Methodology for identifying patients at high risk for osteoporotic fracture. Clin Ther 23:1570–1588PubMedCrossRefGoogle Scholar
  66. 66.
    Colón-Emeric CS, Pieper CF, Artz MB (2002) Can historical and functional risk factors be used to predict fractures in community-dwelling older adults? Development and validation of a clinical tool. Osteoporos Int 13:955–961PubMedCrossRefGoogle Scholar
  67. 67.
    Van Staa T-P, Geusens P, Pols HAP, De Laet C, Leufkens HCM, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Q J Med 98:191–198Google Scholar
  68. 68.
    van Staa TP, Leufkens H-GM, Cooper C (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508–514PubMedCrossRefGoogle Scholar
  69. 69.
    McGrother CW, Donaldson M-MK, Clayton D, Abrams KR, Clarke M (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporos Int 13:89–96PubMedCrossRefGoogle Scholar
  70. 70.
    Walter LC, Lui LY, Eng C, Covinsky KE (2003) Risk of hip fracture in disabled community-living older adults. J Am Geriatr Soc 51:50–55PubMedCrossRefGoogle Scholar
  71. 71.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  72. 72.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Maliee MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRefGoogle Scholar
  73. 73.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain J III, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Sammoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRefGoogle Scholar
  74. 74.
    Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
  75. 75.
    Kanis JA, Barton I, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16:475–482CrossRefGoogle Scholar
  76. 76.
    McCloskey EV, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with post-menopausal or secondary osteoporosis: results of a double blind placebo-controlled 3 year study. J Bone Miner Res 19:728–736PubMedCrossRefGoogle Scholar
  77. 77.
    Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawieki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res, in pressGoogle Scholar
  78. 78.
    Marcus R, Wang O, Satterwhite J et al (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23PubMedCrossRefGoogle Scholar
  79. 79.
    Johnell O, Kanis JA, Black DM et al (2004) Association between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 19:764–772PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • J. A. Kanis
    • 1
  • A. Oden
    • 2
  • O. Johnell
    • 3
  • H. Johansson
    • 2
  • C. De Laet
    • 4
  • J. Brown
    • 5
  • P. Burckhardt
    • 6
  • C. Cooper
    • 7
  • C. Christiansen
    • 8
  • S. Cummings
    • 9
  • J. A. Eisman
    • 10
  • S. Fujiwara
    • 11
  • C. Glüer
    • 12
  • D. Goltzman
    • 13
  • D. Hans
    • 14
  • M.-A. Krieg
    • 15
  • A. La Croix
    • 16
  • E. McCloskey
    • 1
  • D. Mellstrom
    • 17
  • L. J. MeltonIII
    • 18
  • H. Pols
    • 19
  • J. Reeve
    • 20
  • K. Sanders
    • 21
  • A-M. Schott
    • 22
  • A. Silman
    • 23
  • D. Torgerson
    • 24
  • T. van Staa
    • 25
  • N. B. Watts
    • 26
  • N. Yoshimura
    • 27
  1. 1.WHO Collaborating Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Consulting StatisticianGothenburgSweden
  3. 3.Department of OrthopaedicsMalmö General HospitalMalmoSweden
  4. 4.Scientific Institute of Public HealthBrusselsBelgium
  5. 5.Department of RheumatologySans Ospedale University de QuebecQuebecCanada
  6. 6.Department of MedicineCHUV University HospitalLausanneSwitzerland
  7. 7.MRC Epidemiology UnitSouthampton General HospitalSouthamptonUK
  8. 8.CCBRBallerupDenmark
  9. 9.SF Coordinating CenterSan FranciscoUSA
  10. 10.Bone and Mineral Research Program, Garvan Institute of Medical ResearchSt Vincent’s, Hospital and University of New South WalesSydneyAustralia
  11. 11.Department of Clinical StudiesRadiation Effects Research FoundationHiroshimaJapan
  12. 12.Medizinische PhysikUniversitas Klinikum Schleswig-HosteinKeilGermany
  13. 13.Department of MedicineMcGill UniversityMontrealCanada
  14. 14.Nuclear Medicine DivisionGeneva University HospitalGenevaSwitzerland
  15. 15.CHUV University HospitalLausanneSwitzerland
  16. 16.Fred Hutchinson Cancer Research CenterSeattleUSA
  17. 17.Department of Geriatric MedicineGoteborg UniversityGothenburgSweden
  18. 18.Division of EpidemiologyMayo ClinicRochesterUSA
  19. 19.Department of Internal MedicineErasmus Medical Centre RotterdamRotterdamThe Netherlands
  20. 20.Strangeway’s Research LaboratoryWort’s CausewayCambridgeUK
  21. 21.Department of Clinical and Biomedical SciencesUniversity of MelbourneBarwon HealthAustralia
  22. 22.INSERM U831Hospices Civils de LyonLyonFrance
  23. 23.ARC Epidemiology UnitUniversity of ManchesterManchesterUK
  24. 24.Department of Health SciencesUniversity of YorkYorkshireUK
  25. 25.Department of Pharmaco-epidemiology and PharmacotherapyUniversity of UtrechtHollandThe Netherlands
  26. 26.University of Cincinnati College of MedicineCincinnatiUSA
  27. 27.Joint Disease Research, Graduate School of MedicineUniversity of TokyoTokyoJapan

Personalised recommendations